The paper discusses the efficacy of siRNA-based therapies but lacks quantitative analysis or comparative metrics to substantiate the claims about treatment superiority. For instance, while Figure 3 depicts a schematic representation of siRNA and chemotherapy co-delivery, there is no experimental data validating the synergistic effects of this approach in vivo or in vitro.
Could the authors provide more empirical evidence or cite specific studies demonstrating the efficacy of this co-delivery strategy?
Furthermore, the absence of statistical analysis or confidence intervals for the preclinical results described in the review raises questions about the robustness of the cited data. Addressing these gaps would significantly enhance the scientific rigor and practical applicability of the conclusions.